Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Qiagen and BioBay Announce Translational Medicine JV

publication date: May 28, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Qiagen, a Dutch molecular diagnostics company that provides sample and assay technologies, will set up a translational medicine R&D JV with Suzhou’s BioBay Life Science Park. The JV will provide discovery and validation of biomarkers from which it will create companion diagnostics for the Chinese market. Its customers are expected to be domestic and international pharma that are located in BioBay and elsewhere in China. Both entities will be presenting at the ChinaBio® Partnering Forum on May 30. More details....

Stock Symbol: (NSDQ: QGEN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...